Synairgen plc
('Synairgen' or the 'Company')
Exercise of Share Options and Total Voting
Rights
Southampton, UK - 30 October 2024:
Synairgen plc (LSE: SNG), the respiratory company developing
SNG001, an investigational formulation for inhalation containing
the broad-spectrum antiviral protein interferon beta, announces
that it has allotted a total of 1,285,722 new ordinary shares of 1
penny each in the capital of the Company ("Ordinary Shares")
following the exercise of options by an ex-employee of the
Company.
Application has been made to the
London Stock Exchange for the 1,285,722 new Ordinary Shares to be
admitted to trading on AIM ("Admission") and it is expected that
Admission will become effective and trading will commence at 8.00
a.m. on 5 November 2024.
Following Admission, the total
number of Ordinary Shares in issue will be 202,660,697 and the
total number of voting rights will therefore be 202,660,697. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
share capital of the Company under the FCA's Disclosure Guidance
and Transparency Rules.
For
further enquiries, please contact:
Synairgen plc
Media@synairgen.com
Tel: + 44 (0) 23 8051
2800
Cavendish Capital Markets Limited (NOMAD and Joint
Broker)
Geoff Nash, Camilla Hume, Trisyia
Jamaludin (Corporate Finance)
Sunila de Silva (ECM)
Nigel Birks - Life Science
Specialist Sales
Tel: + 44 (0) 20 7220
0500
Deutsche Numis (Joint Broker)
Freddie Barnfield, Duncan Monteith,
Euan Brown
Tel: + 44 (0) 20 7260
1000
ICR
Healthcare (Financial Media and Investor
Relations)
Mary-Jane Elliott, Namrata Taak,
Lucy Featherstone
synairgen@icrhealthcare.com
Tel: +44 (0) 20 3709 5700
Notes for
Editors
About Synairgen
Synairgen is a UK-based respiratory
company focused on drug discovery and the development of SNG001
(inhaled interferon beta) as potentially the first host-targeted,
broad-spectrum antiviral treatment delivered directly into the
lungs for severe viral lung infections.
Millions of people globally are
hospitalised every year due to viral lung infections and there are
currently no approved antiviral therapies for the majority of these
patients. Synairgen is developing SNG001 to address this
need.
Synairgen is quoted on AIM (LSE:
SNG). For more information about Synairgen, please see
www.synairgen.com
